Tema Oncology ETF (NASDAQ:CANC) Sees Large Decrease in Short Interest

Tema Oncology ETF (NASDAQ:CANC) was the target of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 1,000 shares, a drop of 37.5% from the October 15th total of 1,600 shares. Based on an average trading volume of 3,200 shares, the days-to-cover ratio is presently 0.3 days.

Tema Oncology ETF Price Performance

Shares of CANC stock traded down $0.22 on Thursday, hitting $27.64. 380 shares of the company’s stock were exchanged, compared to its average volume of 6,734. The company has a 50 day moving average of $28.37 and a 200 day moving average of $28.14. The stock has a market cap of $48.09 million, a P/E ratio of 26.86 and a beta of 1.11. Tema Oncology ETF has a 12 month low of $22.57 and a 12 month high of $30.11.

Institutional Investors Weigh In On Tema Oncology ETF

An institutional investor recently raised its position in Tema Oncology ETF stock. Thrivent Financial for Lutherans boosted its stake in Tema Oncology ETF (NASDAQ:CANC) by 25.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 399,509 shares of the company’s stock after purchasing an additional 80,133 shares during the period. Thrivent Financial for Lutherans owned about 22.96% of Tema Oncology ETF worth $11,351,000 at the end of the most recent quarter.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.